跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,001 条关于
“Nanjing Leads Biolabs”
全部
4,001
临床试验
1,482
药物
181
机构
68
资讯
2,270
去年
Nanjing Leads Biolabs Soars 122% on Hong Kong Debut Following HK$1.1 Billion IPO
去年
Leads Biolabs Advances First-in-China GPRC5D T-Cell Engager LBL-034 to Phase II Trial
去年
Leads Biolabs' LBL-024 Receives FDA Orphan Drug Designation for Neuroendocrine Cancer
去年
Leads Biolabs' LBL-034 Receives FDA Orphan Drug Designation for Multiple Myeloma
去年
Leads Biolabs' LBL-024 Receives FDA Orphan Drug Designation for Neuroendocrine Cancer
8个月前
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Receives FDA Fast Track Designation for Rare Neuroendocrine Cancer
9个月前
Leads Biolabs' LBL-034 Demonstrates 82.5% Response Rate in Relapsed/Refractory Multiple Myeloma at ASH 2025
去年
Leads Biolabs' LBL-024 Receives Breakthrough Therapy Designation in China for EP-NEC
12个月前
FDA Clears First-in-Human Trial for LBL-047, Novel Bispecific Protein Targeting Autoimmune Diseases
前天
Leads Biolabs' PD-L1/4-1BB Bispecific Opamtistomig Delivers 71% ORR in First-Line NSCLC at WCLC 2026
第 1 页,共 227 页
上一页
下一页